Charles Schwab Investment Management Inc. Acquires 74,119 Shares of BioNTech SE (NASDAQ:BNTX)

Charles Schwab Investment Management Inc. raised its position in BioNTech SE (NASDAQ:BNTX - Free Report) by 123.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 134,036 shares of the company's stock after acquiring an additional 74,119 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.06% of BioNTech worth $15,919,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Candriam S.C.A. grew its holdings in BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock valued at $46,526,000 after purchasing an additional 418,695 shares in the last quarter. Baillie Gifford & Co. boosted its position in BioNTech by 0.4% in the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock valued at $986,750,000 after buying an additional 31,773 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in BioNTech by 63.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company's stock valued at $2,249,000 after buying an additional 7,340 shares during the last quarter. Discovery Capital Management LLC CT acquired a new stake in shares of BioNTech during the second quarter valued at about $2,467,000. Finally, Deerfield Management Company L.P. Series C increased its position in shares of BioNTech by 4.3% during the second quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company's stock worth $47,734,000 after acquiring an additional 24,426 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

Analysts Set New Price Targets

BNTX has been the subject of a number of analyst reports. BMO Capital Markets reissued an "outperform" rating on shares of BioNTech in a report on Monday, December 2nd. Jefferies Financial Group upgraded shares of BioNTech from a "hold" rating to a "buy" rating and increased their price objective for the company from $96.00 to $150.00 in a research note on Tuesday, September 17th. Deutsche Bank Aktiengesellschaft lifted their target price on BioNTech from $95.00 to $150.00 and gave the stock a "buy" rating in a research report on Thursday, September 19th. JPMorgan Chase & Co. reduced their price objective on BioNTech from $124.00 to $122.00 and set a "neutral" rating on the stock in a research note on Tuesday, November 26th. Finally, Evercore ISI upgraded shares of BioNTech from an "in-line" rating to an "outperform" rating and boosted their target price for the company from $110.00 to $125.00 in a research note on Tuesday, November 19th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, BioNTech currently has a consensus rating of "Moderate Buy" and an average target price of $138.67.

BioNTech Stock Up 2.4 %

Shares of BioNTech stock traded up $2.88 during midday trading on Friday, hitting $121.72. The company's stock had a trading volume of 992,408 shares, compared to its average volume of 1,076,621. The firm has a market capitalization of $29.18 billion, a P/E ratio of -57.96 and a beta of 0.22. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The stock has a 50-day simple moving average of $113.91 and a 200-day simple moving average of $99.60.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts' consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm's quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.73 EPS. As a group, sell-side analysts expect that BioNTech SE will post -3.72 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.